Positron, through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), has executed a memorandum of understanding with the Institute of Nuclear Research (INR) of Troitsk, Russia. MIT and INR will collaborate on strontium-82 production beginning with a pharmaceutical ingredient validation exercise in 2012.
The Texas Department of State Health Services-Radiation Control Program has granted Positron's wholly owned subsidiary, Manhattan Isotope Technology, approval of its radioactive materials license amendment.
Positron has acquired all of the assets and business operations and retained all employees of Manhattan Isotope Technology (MIT). In exchange, MIT will receive cash advances, assumption of certain indebtedness and earn-out consideration of $3.5 million, based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.
Positron has received a nuclear pharmacy license from the Indiana Board of Pharmacy for its Crown Point, Ind., manufacturing facility.
Molecular imaging company Positron has signed a letter of intent to buy Manhattan Isotope Technology (MIT), a strontium-82 (SR-82) product specialist, for an undisclosed amount.
Positron, a molecular imaging company specializing in nuclear cardiology, has relocated its PosiRx manufacturing, product research and development facility. The new office is approximately three miles from its current Fishers, Ind., location.
Positron, a nuclear cardiology company, has executed a memorandum of understanding with the City of Noblesville, Ind., to relocate its corporate headquarters, research & development and product manufacturing facilities to Noblesville.
|
|
|
|
RSS 
